NCT07469085

A Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Participants.

A Randomized, Double-blind, Placebo-controlled, Single-ascending-dose Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SV003 in Healthy Participants.

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. · Industry
• Sex: All
• Age: 18 Years – 45 Years
• Healthy volunteers: Accepted

Summary

The objective of this clinical study is to evaluate the safety, tolerability, pharmacokinetic, and pharmacodynamic profiles of SV003 in healthy subjects.

Conditions

• Healthy Participants

Interventions

Type	Name	Description
DRUG	SV003	SV003：Single-dose
DRUG	Placebo	Placebo ： Single-dose

Timeline

• Start date: 2026-04-04
• Primary completion: 2026-10-31
• Completion: 2027-03-31
• First posted: 2026-03-13
• Last updated: 2026-04-08

Locations

1 site across 1 country: China